Incyte Corporation Release: Jakafi® (Ruxolitinib) Continues To Show Improved Overall Survival For Patients With Myelofibrosis In Further Analyses Of Phase III Data Presented At 2013 American Society of Hematology
Published: Dec 09, 2013
NEW ORLEANS--(BUSINESS WIRE)--Incyte Corporation (Nasdaq: INCY) announced today that more than 35 analyses from clinical studies of Jakafi® (ruxolitinib) were presented at the 2013 American Society of Hematology (ASH) Annual Meeting from Dec. 7 to 10 in New Orleans. Jakafi, an oral JAK1/JAK2 inhibitor, is FDA-approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF).
Help employers find you! Check out all the jobs and post your resume.